Urogen Pharma Ltd (NASDAQ:URGN) Q2 2022 Earnings Conference Call August 11, 2022 10:00 AM ET
Company Participants
Vincent Perrone - Senior Director, IR
Elizabeth Barrett - President, CEO & Director
Mark Schoenberg - Chief Medical Officer
Jeffrey Bova - Chief Commercial Officer
Dong Kim - CFO
Conference Call Participants
Christopher Howerton - Jefferies
Raghuram Selvaraju - H.C. Wainwright & Co.
Boris Peaker - Cowen and Company
Matthew Kaplan - Ladenburg Thalmann & Co.
Leland Gershell - Oppenheimer
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the UroGen Pharma second quarter 2022 update conference call. It's my pleasure to hand the call over to Vincent Perrone, Senior Director of Investor Relations for your [Technical Difficulty]. Please go ahead.
Vincent Perrone
Thank you, operator. Good morning, everyone. And welcome to UroGen Pharma Second Quarter 2022 Financial Results and Business Update Conference Call. Earlier today we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended June 30, 2022. The press release can be accessed on the investors portion of our website at investors.urogen.com. Joining me today are Liz Barrett, President and CEO; Dr. Mark Schoenberg, Chief Medical Officer; Jeff Bova, Chief Commercial Officer; and Dong Kim, Chief Financial Officer.
During today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing commercialization activities relating to Jelmyto, our ongoing and planned research efforts and clinical trials, the potential benefits of Jelmyto and our product candidates, data presentations, regulatory filings, future revenue opportunities, potentially reaching cash flow breakeven by 2025, the availability of the second tranche of our term loan facility, and 2022 financial guidance, among other things. These forward-looking statements are based on current information assumptions, and expectations that are subject to change. A description of potential risks can be found in our earnings press release and latest SEC disclosure documents, including under the risk factors heading up our quarterly report on Form 10-Q for the quarter ended June 30, 2020 filed today. You are cautioned not to place undue reliance on these forward-looking statements and UroGen disclaims any obligation to update these statements.
I'll now turn the call over to Liz. Liz?
Elizabeth Barrett
Thank you, Vincent, and thank you to everyone joining us today. As summarized in this morning's press release, our progress during the second quarter of 2022 can primarily be viewed along three lines. First is the continued growth of our Jelmyto revenue. Second is the on pace enrollment of our clinical programs, and the third is further strengthening of the body of evidence underscoring the benefit of Jelmyto in a real world setting.